CDER’s Pharmaceutical Quality Office Expected To Launch In Early 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
The reorganization will move manufacturing surveillance beyond inspections to include standards of quality focused on the risks of a product or company, Office of Pharmaceutical Science Acting Director Keith Webber says.